Upon submission, in your cover letter, please include the names of at least five potential reviewers, in the relevant field of research, to review your manuscript. In light of this, please ensure that there are no conflicts of interest.
Call for Papers: Three-dimensional (3D) cell culture for cancer research
Hereditas is calling for submissions to our Collection on Three-dimensional (3D) cell culture for cancer research. This Collection explores the development of 3D cell culture for cancer research and cancer biology through 3D cell culture strategies.
Call for Papers: Single-cell multi-omic analysis of cancer interactome
Hereditas is calling for submissions that develop innovative computational methods to integrate these multi-omic data, leveraging existing datasets or focusing on cell type-specific interactions, to uncover novel insights into cancer.
Call for Papers: Deep learning the genome
Hereditas is calling for submissions to our Collection on "Deep learning the genome".
Featured Comment: Novel variants require established frameworks: emphasizing the role of ISTH diagnostic and classification guidelines in congenital fibrinogen disorders
This commentary aims to highlight the importance of applying the diagnostic and classification guidelines of the International Society on Thrombosis and Haemostasis (ISTH), along with standardized bleeding assessment tools, in the evaluation of patients with congenital fibrinogen disorders. Additionally, it addresses key laboratory methodologies relevant to the diagnosis of these conditions. We believe that this commentary will contribute meaningfully to the ongoing discussions and promote the adoption of standardized approaches in the assessment of rare congenital fibrinogen disorders.
Mustafa Vakur Bor
Image: © SciePro / stock.adobe.com
Additional Cover Letter Guidelines
Aims and scope
Hereditas publishes original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of human, plant, animal and microbial genetics and epigenetics. Topics of interest also include cancer genetics, cancer biology, non-coding RNA, Data Mining, and Genome Technology.
Image: 3D Render of DNA
© Muhammad / Generated with AI / Stock.adobe.com
Articles
-
-
Identification and validation of ANXA3 and SOCS3 as biomarkers for acute myocardial infarction related to sphingolipid metabolism
-
Structural and functional assessment of TBX20 gene variants in pediatric ventricular septal defect
-
EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines
-
In vitro activity of Houttuynia cordata against bacteria isolated from diabetic foot
-
Adaptation of human skin color in various populations
-
Genetic structure, divergence and admixture of Han Chinese, Japanese and Korean populations
-
Population genomics of East Asian ethnic groups
-
The reversal of human phylogeny: Homo left Africa as erectus, came back as sapiens sapiens
-
Detect accessible chromatin using ATAC-sequencing, from principle to applications
Previous content
Hereditas launched with BioMed Central in 2015, transferring from its previous publisher Wiley. All back content is available in the archive.
Editor-in-Chief
Ramin Massoumi, Lund University
Dr. Ramin Massoumi is a Professor and Principal Investigator at Lund University, Sweden. After earning a PhD from Lund University and completing postdoctoral training at the Max Planck Inst. for Biochemistry in Germany, Dr. Massoumi now leads a research group focused on cancer biology and the development of novel anticancer drugs. Dr. Massoumi has received several prestigious awards, including grants from the European Research Council and Novo Nordisk. As the founder of the Company IVRS, Dr. Massoumi contributes to cancer research both academically and commercially. In addition to serving on the editorial boards of several journals, Dr. Massoumi became Editor-in-Chief of Hereditas in 2024.
Society information
The Mendelian Society of Lund was founded in 1910 and except for a short break during 1912-1916 has been active ever since. In 1920, the Society started to publish Hereditas, a scientific journal in genetics. In the post-genomic era, the scope of Hereditas has evolved to include any research on genomic analysis.
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Article Collections
- Sign up for article alerts and news from this journal
-
Official journal of
-
The Mendelian Society of Lund has been publishing the journal Hereditas since 1920.
-
Follow
Annual Journal Metrics
-
Citation Impact
Journal Impact Factor: 2.5 (2024)
5-year Journal Impact Factor: 2.6 (2024)
Source Normalized Impact per Paper (SNIP): 0.612 (2024)
SCImago Journal Rank (SJR): 0.596 (2024)Speed
Submission to first editorial decision (median days): 10
Submission to acceptance (median days): 110Usage 2024
Downloads: 239,465
Altmetric mentions: 157